Roche subsidiary Foundation Medicine agreed to buy Saga Diagnostics to expand its molecular residual disease (MRD) portfolio, paying up to $595 million. The acquisition brings Saga’s Pathlight tumor-informed MRD platform into Foundation’s mix, with plans to leverage Roche sequencing and Digital LightCycler PCR technologies to enable decentralized MRD testing globally.